These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

235 related articles for article (PubMed ID: 15577644)

  • 1. CADA, a novel CD4-targeted HIV inhibitor, is synergistic with various anti-HIV drugs in vitro.
    Vermeire K; Princen K; Hatse S; De Clercq E; Dey K; Bell TW; Schols D
    AIDS; 2004 Nov; 18(16):2115-25. PubMed ID: 15577644
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CADA, a potential anti-HIV microbicide that specifically targets the cellular CD4 receptor.
    Vermeire K; Brouwers J; Van Herrewege Y; Le Grand R; Vanham G; Augustijns P; Bell TW; Schols D
    Curr HIV Res; 2008 May; 6(3):246-56. PubMed ID: 18473788
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Susceptibility of HIV-2, SIV and SHIV to various anti-HIV-1 compounds: implications for treatment and postexposure prophylaxis.
    Witvrouw M; Pannecouque C; Switzer WM; Folks TM; De Clercq E; Heneine W
    Antivir Ther; 2004 Feb; 9(1):57-65. PubMed ID: 15040537
    [TBL] [Abstract][Full Text] [Related]  

  • 4. New developments in anti-HIV chemotherapy.
    De Clercq E
    Biochim Biophys Acta; 2002 Jul; 1587(2-3):258-75. PubMed ID: 12084468
    [TBL] [Abstract][Full Text] [Related]  

  • 5. New developments in anti-HIV chemotherapy.
    De Clercq E
    Curr Med Chem; 2001 Nov; 8(13):1543-72. PubMed ID: 11562282
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mismatched double-stranded RNA (polyI-polyC(12)U) is synergistic with multiple anti-HIV drugs and is active against drug-sensitive and drug-resistant HIV-1 in vitro.
    Essey RJ; McDougall BR; Robinson WE
    Antiviral Res; 2001 Sep; 51(3):189-202. PubMed ID: 11448730
    [TBL] [Abstract][Full Text] [Related]  

  • 7. New anti-HIV agents and targets.
    De Clercq E
    Med Res Rev; 2002 Nov; 22(6):531-65. PubMed ID: 12369088
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Drug resistance and drug combination features of the human immunodeficiency virus inhibitor, BCH-10652 [(+/-)-2'-deoxy-3'-oxa-4'-thiocytidine, dOTC].
    Taylor DL; Ahmed PS; Tyms AS; Wood LJ; Kelly LA; Chambers P; Clarke J; Bedard J; Bowlin TL; Rando RF
    Antivir Chem Chemother; 2000 Jul; 11(4):291-301. PubMed ID: 10950391
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Emerging anti-HIV drugs.
    De Clercq E
    Expert Opin Emerg Drugs; 2005 May; 10(2):241-73. PubMed ID: 15934866
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anti-HIV drugs.
    De Clercq E
    Verh K Acad Geneeskd Belg; 2007; 69(2):81-104. PubMed ID: 17550060
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anti-HIV drugs: 25 compounds approved within 25 years after the discovery of HIV.
    De Clercq E
    Int J Antimicrob Agents; 2009 Apr; 33(4):307-20. PubMed ID: 19108994
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antiretroviral treatment. HIV infection in adults: better-defined first-line treatment.
    Prescrire Int; 2004 Aug; 13(72):144-50. PubMed ID: 15532140
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Potent synergistic anti-human immunodeficiency virus (HIV) effects using combinations of the CCR5 inhibitor aplaviroc with other anti-HIV drugs.
    Nakata H; Steinberg SM; Koh Y; Maeda K; Takaoka Y; Tamamura H; Fujii N; Mitsuya H
    Antimicrob Agents Chemother; 2008 Jun; 52(6):2111-9. PubMed ID: 18378711
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synergistic effect resulting from combinations of a bifunctional HIV-1 antagonist with antiretroviral drugs.
    Xu W; Wang Q; Yu F; Lu L; Jiang S
    J Acquir Immune Defic Syndr; 2014 Sep; 67(1):1-6. PubMed ID: 24977378
    [TBL] [Abstract][Full Text] [Related]  

  • 15. APHS can act synergically with clinically available HIV-1 reverse transcriptase and protease inhibitors and is active against several drug-resistant HIV-1 strains in vitro.
    Pereira CF; Paridaen JT; van de Bovenkamp M; Middel J; Verhoef J; Nottet HS
    J Antimicrob Chemother; 2003 May; 51(5):1181-9. PubMed ID: 12668583
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vitro inhibition of HIV-1 by Met-SDF-1beta alone or in combination with antiretroviral drugs.
    Rusconi S; Merrill DP; La Seta Catamancio S; Citterio P; Bulgheroni E; Croce F; Chou TC; Yang OO; Herrmann SH; Galli M; Hirsch MS
    Antivir Ther; 2000 Sep; 5(3):199-204. PubMed ID: 11075940
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combinations of 3-hydroxyphthalic anhydride-modified ovalbumin with antiretroviral drug-based microbicide candidates display synergistic and complementary effects against HIV-1 infection.
    Li L; Tan S; Lu H; Lu L; Yang J; Jin H; Liu S; Jiang S
    J Acquir Immune Defic Syndr; 2011 Apr; 56(5):384-92. PubMed ID: 21239999
    [TBL] [Abstract][Full Text] [Related]  

  • 18. New developments in anti-HIV chemotherapy.
    De Clercq E
    Farmaco; 2001; 56(1-2):3-12. PubMed ID: 11347962
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vitro evaluation of the effect of temporary removal of HIV drug pressure.
    Witvrouw M; Pannecouque C; Desmyter J; De Clercq E; Andries K
    Antiviral Res; 2000 Jun; 46(3):215-21. PubMed ID: 10867159
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetics of antiretrovirals in pregnant women.
    Mirochnick M; Capparelli E
    Clin Pharmacokinet; 2004; 43(15):1071-87. PubMed ID: 15568888
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.